ATE324441T1 - Htk-ligand - Google Patents

Htk-ligand

Info

Publication number
ATE324441T1
ATE324441T1 AT95926279T AT95926279T ATE324441T1 AT E324441 T1 ATE324441 T1 AT E324441T1 AT 95926279 T AT95926279 T AT 95926279T AT 95926279 T AT95926279 T AT 95926279T AT E324441 T1 ATE324441 T1 AT E324441T1
Authority
AT
Austria
Prior art keywords
ligand
htk
ligands
htk ligand
receptor
Prior art date
Application number
AT95926279T
Other languages
English (en)
Inventor
Brian D Bennett
William Matthews
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23062090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324441(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE324441T1 publication Critical patent/ATE324441T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT95926279T 1994-07-20 1995-07-14 Htk-ligand ATE324441T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27772294A 1994-07-20 1994-07-20

Publications (1)

Publication Number Publication Date
ATE324441T1 true ATE324441T1 (de) 2006-05-15

Family

ID=23062090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926279T ATE324441T1 (de) 1994-07-20 1995-07-14 Htk-ligand

Country Status (11)

Country Link
US (2) US5624899A (de)
EP (1) EP0773997B2 (de)
JP (1) JPH10501701A (de)
AT (1) ATE324441T1 (de)
AU (1) AU705107B2 (de)
CA (1) CA2194955A1 (de)
DE (1) DE69534962T3 (de)
ES (1) ES2264127T5 (de)
IL (1) IL114668A (de)
MX (1) MX9700486A (de)
WO (1) WO1996002645A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
WO1996026958A2 (en) * 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
WO1998002458A1 (en) 1996-07-16 1998-01-22 Asahi Kasei Kogyo Kabushiki Kaisha Differentiation inhibitor
AUPO754997A0 (en) * 1997-06-25 1997-07-17 Leukaemia Foundation Of Queensland, The Receptor-ligand system and assay therefor
AU9594598A (en) 1997-10-02 1999-04-27 Millennium Pharmaceuticals, Inc. Modulation of lerk-2-mediated cell adhesion
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
DE69925024T2 (de) * 1998-11-20 2006-03-02 Genentech, Inc., South San Francisco Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US7171263B2 (en) * 1999-06-04 2007-01-30 Impulse Dynamics Nv Drug delivery device
US7011943B2 (en) * 2000-09-06 2006-03-14 Transnetyx, Inc. Method for detecting a designated genetic sequence in murine genomic DNA
AU2002212292A1 (en) * 2000-09-29 2002-04-08 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
ES2373715T3 (es) * 2002-05-10 2012-02-08 Medimmune, Llc Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos.
CA2494577A1 (en) * 2002-08-02 2004-02-12 Wyeth Mk2 interacting proteins
EP1553963A4 (de) * 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT
JP4762889B2 (ja) * 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2006523240A (ja) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド ＥｐｈＡ２、低増殖性細胞障害ならびに上皮および内皮の再構成
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
JP4960859B2 (ja) * 2004-03-12 2012-06-27 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
EP1602928A1 (de) * 2004-06-01 2005-12-07 Universiteit Maastricht Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen
JP2008514925A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 腫瘍を検出し且つ治療するための組成物及び方法
CA2581423A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
AU2006208068B2 (en) * 2005-01-27 2011-08-04 The Burnham Institute EphB receptor-binding peptides
CA2623387A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
JPWO2007043629A1 (ja) * 2005-10-05 2009-04-16 アキュメンバイオファーマ株式会社 エフリンｂ２を用いる血管新生の抑制方法
RU2450020C2 (ru) * 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BRPI0815399A2 (pt) * 2007-08-13 2019-09-24 Vasgene Therapeutics Inc tratamento de câncer usando anticorpos humanizados que se ligam ephb4
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
JP6158090B2 (ja) * 2011-10-31 2017-07-05 ダニエル・ジェイ・カポン 非ペプチドヒンジ部含有フレキシブル抗体様分子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128722A1 (en) * 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
CA2148484A1 (en) * 1992-11-13 1994-05-26 Stewart Lyman Novel cytokine designated elk ligand
JP3686084B2 (ja) * 1994-04-04 2005-08-24 リジエネロン・フアーマシユーテイカルズ・インコーポレーテツド 生物学上活性なｅｐｈ族リガンド
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna

Also Published As

Publication number Publication date
EP0773997B2 (de) 2012-04-25
WO1996002645A3 (en) 1996-02-15
WO1996002645A2 (en) 1996-02-01
DE69534962T2 (de) 2007-02-08
AU705107B2 (en) 1999-05-13
AU3008995A (en) 1996-02-16
US5864020A (en) 1999-01-26
JPH10501701A (ja) 1998-02-17
IL114668A0 (en) 1995-11-27
DE69534962D1 (en) 2006-06-01
IL114668A (en) 2007-07-24
DE69534962T3 (de) 2012-10-04
EP0773997B1 (de) 2006-04-26
EP0773997A2 (de) 1997-05-21
ES2264127T5 (es) 2012-07-04
ES2264127T3 (es) 2006-12-16
MX9700486A (es) 1997-04-30
CA2194955A1 (en) 1996-02-01
US5624899A (en) 1997-04-29

Similar Documents

Publication Publication Date Title
ATE324441T1 (de) Htk-ligand
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
FI20022285L (fi) Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja
EP1308461A3 (de) Antikörper gegen Beta-Amyloiden oder deren Abarten, und deren Verwendungen
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
NL300106I1 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
DK0751992T3 (da) Karendotelvækstfaktor 2
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
ATE199259T1 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
ATE167896T1 (de) Aus mehreren domänen bestehende hämatopoese- stimulatoren
EP0821728A4 (de) Tie-2 liganden, herstellungsverfahren und verwendung
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
DE69325096D1 (de) Morphinderivate sowie deren konjugate und labels mit proteinen und polypeptiden
YU79491A (sh) Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina
MXPA02008239A (es) Gen humano de la esquizofrenia.
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
EP0854185A3 (de) Rezeptor-Proteine zu Bestimmungszwecke und Liganden
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
ATE234918T1 (de) Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
EP0635016A4 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden.
EP1212340A4 (de) 29 mit krebs im zusammenhang stehende menschliche proteine
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0773997

Country of ref document: EP